Skip to main content
. Author manuscript; available in PMC: 2018 Feb 9.
Published in final edited form as: Gynecol Oncol. 2009 Jun 12;114(3):472–479. doi: 10.1016/j.ygyno.2009.05.012

Table 3.

Association between c-MYC amplification or polysomy for chromosome 8 and clinical response or disease status after completion of first-line treatment.

Clinical response Disease status


No response Responsea p-value* No evidence of disease Positive for diseaseb p-value*
c-MYC amplificationc
≥2 c-MYC/CEP8 copies
No 7 (18.4%) 31 (81.6%) 22 CR 1.000 14 (22.2%) 49 (77.8%) 34 + RL 1.000
9 PR 15 + DP
  Yes 3 (20.0%) 12 (80.0%) 5 CR 6 (24.0%) 19 (76.0%) 14 + RL
7 PR 5 + DP
c-MYC amplificationd
≥ 1.5 c-MYC/CEP8 copies
  No 3 (13.6%) 19 (86.4%) 15 CR 0.494 10 (28.6%) 25 (71.4%) 18 + RL 0.310
4 PR 7 + DP
  Yes 7 (22.6%) 24 (77.4%) 12 CR 10 (18.9%) 43 (81.1%) 30 + RL
12 PR 13 + DP
Polysomy for chromosome 8e4 CEP8 copies
≥ 4 CEP8 copies
  No 8 (23.5%) 26 (76.5%) 17 CR 0.299 15 (22.7%) 51 (77.3%) 37 + RL 1.000
9 PR 14 + DP
  Yes 2 (10.5%) 17 (89.5%) 10 CR 5 (22.7%) 17 (77.3%) 11 + RL
7 PR 6 + DP
a

Response includes a complete response (CR) or a partial response (PR).

b

Positive for disease includes those with microscopic or gross disease at reassessment laparotomy (+ RL) or with clinical evidence of disease progression documented during first-line treatment (+ DP).

c

c-MYC amplification was categorized as ‘No’ when tumors had <2 copies of c-MYC/CEP8 per cell or ‘Yes’ when tumors had ≥2 copies of c-MYC/CEP8 per cell.

d

c-MYC amplification was categorized as ‘No’ when tumors had <1.5 copies of c-MYC/CEP8 per cell or ‘Yes’ when tumors had ≥1.5 copies of c-MYC/CEP8 per cell.

e

Polysomy for chromosome 8 was categorized as ‘No’ when tumors had <4 copies of CEP8 per cell or ‘Yes’ when tumors had ≥4 copies of CEP8 per cell.

*

Fisher's Exact Test.